Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report)’s stock price dropped 1.2% during trading on Thursday . The company traded as low as $13.40 and last traded at $13.43. Approximately 1,877 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 2,160 shares. The stock had previously closed at $13.60.
Finch Therapeutics Group Stock Down 1.2%
The business’s 50 day moving average is $13.16 and its 200 day moving average is $12.93. The company has a market cap of $21.57 million, a P/E ratio of -1.52 and a beta of 1.25.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Recommended Stories
- Five stocks we like better than Finch Therapeutics Group
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- Conference Calls and Individual Investors
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- ETF Screener: Uses and Step-by-Step Guide
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
